Coya Therapeutics (COYA) was the only company to complete an IPO in the last week of 2022. China-based ASIC chip designer Intchains (ICG) and Hong Kong-based wealth and asset manager Prestige Wealth (PWM)...read more
Coya Therapeutics, a Phase 2 biotech developing regulatory T-cell therapies for various indications, raised $15 million by offering 3.1 million units at $5. Each unit consists of one share of common stock and one warrant to purchase one-half of a share,...read more
Coya Therapeutics, a Phase 2 biotech developing regulatory T-cell therapies for various indications, announced terms for its IPO on Monday. The Houston, TX-based company plans to raise $15 million by offering 3.1 million shares at $5. Each share will be sold...read more
After delaying its offering, Acrivon Therapeutics (ACRV) completed the week’s sole IPO. In the pipeline, seven companies submitted initial filings, including three planning to raise $100 million. Biotech ...read more
US IPO Weekly Recap: Foreign issuers and a direct listing cap off 2022 IPO filings
Coya Therapeutics (COYA) was the only company to complete an IPO in the last week of 2022. China-based ASIC chip designer Intchains (ICG) and Hong Kong-based wealth and asset manager Prestige Wealth (PWM)...read more
Regulatory T-cell biotech Coya Therapeutics prices unit offering at $5
Coya Therapeutics, a Phase 2 biotech developing regulatory T-cell therapies for various indications, raised $15 million by offering 3.1 million units at $5. Each unit consists of one share of common stock and one warrant to purchase one-half of a share,...read more
Regulatory T-cell biotech Coya Therapeutics sets terms for $15 million IPO, offering units
Coya Therapeutics, a Phase 2 biotech developing regulatory T-cell therapies for various indications, announced terms for its IPO on Monday. The Houston, TX-based company plans to raise $15 million by offering 3.1 million shares at $5. Each share will be sold...read more
US IPO Weekly Recap: Biotech Acrivon completes the week’s sole IPO while big deals join the pipeline
After delaying its offering, Acrivon Therapeutics (ACRV) completed the week’s sole IPO. In the pipeline, seven companies submitted initial filings, including three planning to raise $100 million. Biotech ...read more